Pharming Group (NASDAQ:PHAR) Hits New 12-Month High – Here’s What Happened

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $18.20 and last traded at $18.1050, with a volume of 1567 shares. The stock had previously closed at $18.09.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Zacks Research raised Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Pharming Group currently has a consensus rating of “Buy” and a consensus target price of $38.00.

Pharming Group Stock Performance

The business has a 50 day moving average price of $15.88 and a two-hundred day moving average price of $13.67. The stock has a market cap of $1.24 billion and a PE ratio of -1,808.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.16 and a quick ratio of 2.39.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.05. The firm had revenue of $97.30 million for the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%. As a group, equities research analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.